Clinical Trial Update: Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 trial of a geldanamycin analogue in patients with advanced solid tumors or Non-Hodgkin lymphoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
• Follicular Lymphoma
• Nodal Marginal Zone B-cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Geldanamycin analogue (geldanamycin analogue)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma | Phase 1 | Status: TERMINATED